Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 September 2011
Topic area
  • Cancer

Scoped within Batch 19

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Kate Moore
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
5 February 2013

NICE have been informed by the manufacturer of ridaforolimus that the Marketing Authorisation application for ridaforolimus with the EMA has been withdrawn. View further information.

This appraisal consequently remains suspended and NICE will continue to monitor any developments.

31 May 2012 The manufacturer of ridaforolimus has informed us that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal.

For further information on our processes and methods, please see our CHTE processes and methods manual